Aromasin Húðuð tafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aromasin húðuð tafla 25 mg

pfizer aps - exemestanum inn - húðuð tafla - 25 mg

Targretin Evrópusambandið - íslenska - EMA (European Medicines Agency)

targretin

eisai gmbh - bexarótín - eitilæxli, t-frumur, húð - Æxlishemjandi lyf - targretin hylki eru ætlaðar til meðhöndlunar á einkennum í húð hjá sjúklingum með sjúkdóm í t-frumu eitilfrumugerð í langt gengnu stigi, sem eru ónæmir fyrir að minnsta kosti einum almennri meðferð.

Seroxat Filmuhúðuð tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

seroxat filmuhúðuð tafla 20 mg

glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg

Seroxat Filmuhúðuð tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

seroxat filmuhúðuð tafla 10 mg

glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 10 mg

Fluoxetin WH Hart hylki 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fluoxetin wh hart hylki 20 mg

williams & halls ehf - fluoxetine hydrochloride - hart hylki - 20 mg

Paxetin Filmuhúðuð tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

paxetin filmuhúðuð tafla 20 mg

teva b.v.* - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg

Verzenios Evrópusambandið - íslenska - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - brjóstakrabbamein - Æxlishemjandi lyf - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Bupropion Teva Tafla með breyttan losunarhraða 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bupropion teva tafla með breyttan losunarhraða 300 mg

teva b.v.* - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg

Fluoxetin Viatris (Fluoxetin Mylan) Hart hylki 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fluoxetin viatris (fluoxetin mylan) hart hylki 20 mg

viatris limited - fluoxetinum hýdróklóríð - hart hylki - 20 mg

Fontex Dreifitafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fontex dreifitafla 20 mg

eli lilly danmark a/s - fluoxetinum hýdróklóríð - dreifitafla - 20 mg